The US Food and Drug Administration (FDA) has approved dabrafenib (Tafinlar) with trametinib (Mekinist) for children aged 1 year or older who need systemic treatment for low-grade gliomas that have a ...
Discover comprehensive details about Dabrafenib, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...
The appraisal committee considered evidence submitted by Novartis and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.
The appraisal committee considered evidence submitted by the company that manufactures dabrafenib and a review of this submission by the evidence review group (ERG). Patients in BREAK‑3 were randomly ...
Dabrafenib plus trametinib results in significantly more responses and longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations ...
Dabrafenib (trade name: Tafinlar) has been approved since 2013 for the treatment of adults with advanced melanoma with a BRAF V600 mutation. Reviewers examined in two dossier assessments whether ...
For patients with resected stage III melanoma, adjuvant therapy with dabrafenib plus trametinib is associated with a nonsignificant benefit in terms of overall survival, according to a study published ...
What Is the Role of Dabrafenib Plus Trametinib Adjuvant Therapy in Stage IIIA Melanoma? The following represents disclosure information provided by the author of this manuscript. All relationships are ...
(ChemotherapyAdvisor) – The combination of the selective BRAF inhibitor, dabrafenib, and the MEK inhibitor, trametinib, significantly improved progression-free survival (PFS) in patients with melanoma ...
Two new drugs have been approved by the US Food and Drug Administration (FDA) for use in certain patients with metastatic or unresectable melanoma, along with a diagnostic test to identify patients ...
No positive effects regarding mortality, symptoms and quality of life can be derived from the available data on the use of Dabrafenib in melanoma treatment. The side effects are too concerning, says a ...
What Is the Role of Dabrafenib Plus Trametinib Adjuvant Therapy in Stage IIIA Melanoma? The following represents disclosure information provided by the author of this manuscript. All relationships are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results